Story perspectives

UCLA's Gene Therapy Aims to Cure Alpha Thalassemia

9/18/2025

40 3

Summary

Story summary

UCLA researchers are developing a stem cell gene therapy for alpha thalassemia major, a serious blood disorder.
The therapy employs a viral vector to introduce the missing alpha-globin gene into patients' blood stem cells.
Preclinical studies demonstrated restored hemoglobin production in modified cells.
The therapy aims to eliminate lifelong blood transfusions and donor match requirements.
Funding from the California Institute for Regenerative Medicine will support further studies and FDA submission.

1 of 1

Story summary

UCLA researchers are developing a stem cell gene therapy for alpha thalassemia major, a serious blood disorder.
The therapy employs a viral vector to introduce the missing alpha-globin gene into patients' blood stem cells.
Preclinical studies demonstrated restored hemoglobin production in modified cells.
The therapy aims to eliminate lifelong blood transfusions and donor match requirements.
Funding from the California Institute for Regenerative Medicine will support further studies and FDA submission.